Trial · NCT02835924
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
NCT02835924, Phase 2, Completed, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC. Trials, record NCT02835924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02835924
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
- NCT number
- NCT02835924
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 299 participants, actual
- Lead sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Regorafenib
- First posted
- 2016-07-18
- Last updated
- 2020-03-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria. | 30 months | |
| Secondary | Percentage of total administrated dose over the planned dose accomplished in each arm. | 30 months | |
| Secondary | Dose intensity during the whole treatment. | 30 months | |
| Secondary | Dose intensity during first two cycles. | 2 months | |
| Secondary | Disease control rate (DCR) | 30 months | |
| Secondary | Progression-free survival (PFS) | 30 months | |
| Secondary | Time to treatment failure (TTF) | 30 months | |
| Secondary | Overall survival (OS) | 30 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02835924
GET https://conductscience.org/api/trials/v1/NCT02835924/registered